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A Ab bs st tr ra ac ct t    The epidermis is the outermost layer in the skin, and it is the first line of defence 
against the environment. The epidermis also provides a barrier against loss of fluids 
and electrolytes, which is crucial for life. Essential in the maintenance of this tissue 
is its ability to continually self-renew and regenerate after injury. These two 
characteristics are critically dependent on the ability of the principal epidermal cell 
type, the keratinocyte, to proliferate and to respond to differentiation cues. Indeed, 
the epidermis is a multilayered tissue composed of keratinocyte stem cells and their 
differentiated progeny. Central for the control of cell proliferation is the E2F 
transcription factor regulatory network. This signaling network also includes cyclins, 
cdk, cdk inhibitors and the retinoblastoma (pRb) family of proteins. The biological 
importance of the E2F/pRb pathway is emphasized by the fact that a majority of 
human tumours exhibit alterations that disrupt the ability of pRb proteins to inhibit 
E2F, leading to permanent activation of the latter. Further, E2F is essential for 
normal epidermal regeneration after injury. Other member of the E2F signaling 
pathway are also involved in epidermal development and pathophysiology.  Thus, 
whereas the pRb family of proteins is essential for epidermal morphogenesis, 
abnormal regulation of cyclins and E2F proteins results in tumorgenesis in this 
tissue.  In this review, we discuss the role of each member of this important growth 
regulatory network in epidermal formation, homeostasis and carcinogenesis. 
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1.  Introduction 
Proper regulation of cell proliferation and differentiation is critical for the maintenance of self-renewing tissues, 
such as the epidermis, and is centrally involved in their pathogenesis. In mammalian cells, the E2F family of 
transcription factors is an important downstream effector in a pathway activated by multiple signaling events, which 
controls the expression of genes involved in cell cycle progression, G1/S transition and DNA replication. The E2F 
proteins are downstream components of a growth regulatory pathway that also includes members of the retinoblastoma 
(pRB) family, cyclins, cyclin-dependent kinases (cdk), as well as cdk inhibitors (reviewed in [1, 2, 3]). More recently, 
other E2F targets have been identified, which include genes involved in apoptosis, DNA repair and damage 
checkpoints..  
A substantial body of work has been conducted to decipher how the E2F/pRB network functions, mostly using 
tumour cell lines or serum-starved fibroblasts, and largely in the context of progression from the G0/G1 to the S phases 
of the cell cycle. Several excellent recent reviews discuss these functions of E2F [1, 2, 3]. This review will focus on the 
regulation and role of the E2F growth regulatory network on homeostasis and pathogenesis of the epidermis, a complex 
tissue composed of stem cells and their undifferentiated progeny, as well as keratinocytes at various stages of 
differentiation and varied proliferative potential. 
2.  Embryonic development of the mammalian epidermis 
The skin is the largest organ in the body and is the first line of defence against environmental insults, and microbial 
infection, as well as water and electrolyte loss. The skin is formed by two layers: The outer epidermis and the inner 
dermis. The epidermis is a complex stratified squamous epithelium formed by one basal and several suprabasal layers 
of keratinocytes, which provide barrier functions to the skin (Figure 1). Each epidermal layer contains keratinocytes at 
various stages of differentiation and proliferative potential (reviewed in [4]). In addition, the mammalian epidermis 
contains appendages, such as hair follicles, sebaceous glands, mammary and eccrine sweat glands, teeth and nails.   
During early embryogenesis, the surface epithelium consists of a single-layered, highly proliferative ectoderm, 
present in embryonic day (E) 9-10 murine embryos [5, 6]. Between E9 and E12, the ectoderm undergoes stratification to 
produce a transitory peridermal layer, which is shed later on. The embryonic ectoderm is highly proliferative, as it must 
quickly expand to cover the growing embryo. Additional stratification of the ectoderm between E12 and E15 produces a 
basal and an intermediate layer. The cells in the intermediate layer undergo early terminal differentiation at E15-E16, 
ultimately giving rise to the upper (suprabasal) spinous and granular layers of the epidermis. Formation of epidermal 
appendages involves fate decisions in ectodermal stem cell lineages partly directed by signals originating in the 
underlying mesenchyme (reviewed in [7]).  One of the last events during embryonic epidermal development is the 
acquisition of barrier function, which occurs shortly prior to birth, between E16 and E17 [8]. 
3.  Post-natal epidermis: Architecture, self-renewal and regeneration after injury 
The postnatal epidermis is formed by a lower, basal layer directly in contact with a basement membrane, and 
composed by epidermal stem cells and their committed progeny, termed transit amplifying cells (Fig. 1). As transit 
amplifying cells differentiate, they migrate upwards, sequentially giving rise to the suprabasal spinous, granular and 
cornified layers. The epidermis is continuous with appendages such as hair follicles and sebaceous glands, and 
undergoes constant renewal and remodeling, as cells on the cornified layers are shed and are replenished. In humans 
the epidermis is completely renewed every three weeks [9]. Critical for the self-renewal properties of the epidermis is 
the existence of multipotent stem cells, which can give rise to all lineages of skin epithelia, including interfollicular 
epidermis, hair follicles, and sebaceous glands. Epidermal stem cells are found at various sites, including in or near the 
bulge region of the hair follicle and in interfollicular epidermis [7, 9, 10, 11].  
Wounding of the skin triggers extensive proliferation of epidermal stem cells. Clinically, grafting of cultured 
autologous epidermal stem cells efficiently reconstitutes the epidermis, although appendages are not regenerated, 
indicating that other signals, including those originating in the underlying mesenchyme are necessary for appendage 
formation (reviewed in [12, 13]). Re-epithelialization after wounding is a complex process that requires signals from 
inflammatory cells, dermal fibroblasts and keratinocytes themselves.  The epidermal cells at the wound margin undergo 
pronounced changes, including the acquisition of migratory properties. In the keratinocytes just behind the actively 
migrating cells, a pronounced activation of proliferative pathways takes place, inducing extensive cell division which 
provides new keratinocytes needed to effectively cover the wound. Once this occurs, epidermal cells re-establish the 
basement membrane and initiate stratification, reverting to their resting phenotype. All of these changes involve tight 
regulation of expression and activity of growth regulatory proteins, especially those in the E2F pathway. 
4.  The E2F family 
The E2F family of transcription factors consists of two subgroups termed E2F and DP (reviewed in [1, 2, 3]). In 
mammals, seven E2F and two DP genes have been identified. The functional E2F unit is generally a heterodimer 
containing one E2F and one DP protein, associated through their respective dimerization domains. The exception is 
E2F7, which does not interact with DP proteins, but functions as a homodimer [14, 15, 16]. Structurally, E2F1 through –5 
contain a DNA binding domain, a leucine-zipper dimerization domain for interactions with DP proteins, and a C-
terminal transcriptional activation domain that also mediates interactions with the pRb family of proteins (Fig. 2). E2F1, 
-2 and –3 also contain a cyclin A-binding domain and interact exclusively with pRb, whereas E2F4 and –5 do not bind 
cyclin A and interact preferentially with the two other pRb-related proteins, p107 and p130. E2F6 contains DNA-binding 
and dimerization domains very similar to the other E2F proteins, but lacks pRB-binding and transcriptional activation 
regions. There are two DNA-binding domains in E2F-7, which, remarkably, lacks dimerization and pRB-binding Int. J. Biol. Sci. 2005 1  89
regions. DP proteins have a DNA-binding and a dimerization domain very similar to those found in the E2F subgroup, 
but they lack transcriptional activation and pRB-binding regions. The complexity of the E2F family is increased by the 
existence of multiple splice forms of DP2, E2Fs –3, -6 and –7, although the exact role of each splice form is unclear at 
present. 
A large body of work has characterized the role of E2F in G1/S transition and DNA replication in mammalian cells. 
More recently, a broader function of some E2F proteins in mediating apoptosis, DNA damage and repair has been 
established (reviewed in [1, 17, 18]). Clearly, the breadth of biological activities of E2F factors is accompanied by a large 
variety of gene targets [19, 20], and the presence in E2F complexes of chromatin-modifying factors has emerged as a 
common mechanism involved in transcriptional regulation by E2F [2]. Such association is likely central for the ability of 
E2F-containing complexes to either activate or repress transcription of target genes.  
The generation of mutant mouse models with targeted inactivation of E2F genes has shed light into some of their 
biological roles. Inactivation of E2F1 results in tissue-specific impairment of several functions in epidermal 
keratinocytes, including a marked reduction in proliferation rates, adhesion, migration and chemotaxis in response to 
serum or to transforming growth factor-β (TGF-β). In vivo, these defects result in significantly delayed wound healing 
[21]. In addition, E2F1-/- mice exhibit defective thymocyte apoptosis during normal thymic selection [22, 23], and 
abnormal pancreatic growth and function [24]. E2F2-/- mice develop autoimmune disorders consequent to enhanced T-
lymphocyte proliferation [25], whereas E2F3-null animals exhibit abnormal cardiac function and develop congestive 
heart failure [26], and fibroblasts from these animals show abnormal centrosome amplification [27]. E2F4 is necessary 
for proper haematopoietic and intestinal epithelium maturation [28, 29], whereas E2F5 is indispensable for normal 
development and function of the differentiated choroid plexus epithelium [30].   
5.  The E2F/pRB growth regulatory pathway 
E2F is a downstream component of a signaling network that regulates cell growth, as well as the transition between 
cell proliferation and terminal differentiation. This signaling network also includes cyclins, cdk, cdk inhibitors and the 
pRb family of proteins [1, 2, 3, 31]. In quiescent or terminally differentiated cells, E2Fs form complexes that generally 
containing p130 and, in some cases, pRb. These complexes repress transcription of genes necessary for DNA replication.  
Mitogenic stimulation of quiescent cells induces activation of cyclin D-cdk4(6) complexes, which phosphorylate pRb 
and p130 (Fig. 3). Phosphorylated pRb family proteins dissociate from E2F, and this “free” E2F becomes a 
transcriptional activator, directing the synthesis of factors involved in cell cycle progression and in DNA replication (E. 
g. cyclins E and A, cdk2, DNA polymerase). The biological importance of this pathway is emphasized by the fact that a 
majority of human tumours exhibit alterations that disrupt the ability of pRb proteins to inhibit E2F, leading to 
permanent activation of the latter [32, 33].  
The E2F pathway is a target of many signaling cascades associated with entry into or exit from quiescence [31]. For 
example, activation of the ras and MAPK pathway induces cyclin D expression, pRb (p107 or p130) phosphorylation 
and E2F activation. Senescence and mitogenic inhibitors, such as TGF-β, induce cyclin D/cdk inhibitors, which results in 
the production of hypophosphorylated pRb proteins, which then associate with E2F, forming repressor complexes. 
DNA damage can trigger cell cycle arrest or apoptosis mediated through ATM and E2F1. Finally, signaling pathways 
activated by differentiation can activate E2F-mediated induction of key homeobox and Polycomb group proteins 
involved in development. 
6.  Role and regulation of E2F proteins in epidermal morphogenesis and homeostasis 
The epidermis expresses at least 6 of the seven E2F forms isolated to-date (L. Dagnino, unpublished). During 
murine epidermal development, E2F4 mRNA is first detected in the E12.5 ectoderm, followed by appearance of E2F2 in 
basal cells underneath the intermediate layer in E14.5 embryos. Epidermal stratification at E15.5 triggers differential 
expression of E2F transcripts. E2F2 and E2F4 mRNA are detected in the basal keratinocyte layer and follicle epithelium 
around the dermal papilla, whereas E2F5 mRNA is abundant in the terminally differentiated suprabasal layers [34].  
In primary cultured mouse keratinocytes, E2F1, 2, and 3 protein levels decrease during differentiation induced by 
Ca2+ or bone morphogenetic protein (BMP)-6 [35], although Ca2+-induced differentiation does not decrease E2F1 mRNA 
levels. Ca2+ activates multiple signaling pathways, including protein kinase C (PKC) [36], and the reduction in E2F1 
protein levels in differentiating mouse keratinocytes involves activation of PKC δ and η (Ivanova and Dagnino, 
unpublished observations).  E2F1 mRNA levels and stability decrease in primary human keratinocytes induced to 
differentiate by treatment with interferon γ or 　  phorbol esters, and during senescence [37, 38, 39, 40].  In contrast, E2F1 
protein levels did not decrease in immortalized human HaCaT keratinocytes induced to differentiate. Other differences 
have been reported in the regulation of E2F during differentiation of mouse keratinocytes relative to HaCaT cells. 
Specifically, whereas E2F4 and E2F5 proteins decrease during differentiation induced by serum withdrawal in HaCaT 
cells, induction of differentiation by Ca2+ or BMP-6 in murine keratinocytes does not significantly alter E2F4 levels, but 
results in E2F5 protein upregulation, consistent with the abundant E2F-5 transcripts in the suprabasal epidermal layers 
[35, 41]. The reason for these differences is not clear, and may be related to the distinct nature of the cell models used.  
E2F1 plays a central role in maintaining keratinocytes in a proliferative, undifferentiated state. Specifically, primary 
cultured undifferentiated E2F1-/- keratinocytes exhibit doubling times about seven-fold longer than normal cells due to 
lengthening of the G1 and S phases. These cells also exhibit reduced signaling through integrins, which may partially 
account for their abnormal proliferation phenotype [21]. In contrast, exogenous E2F1 expression induces DNA synthesis 
in terminally differentiated mouse keratinocytes [35], and suppresses expression of the differentiation markers keratin 
K10, loricrin and involucrin in human cells induced to differentiate with Ca2+ treatment [41, 42, 43]. E2F1 also plays a 
role in the expression of the tumor suppressor gene BRCA1. Transgenic mice that specifically express E2F1 in the basal 
layer exhibit BRCA1 levels about 4-fold higher than wild type littermates [44]. Although the biological significance of Int. J. Biol. Sci. 2005 1  90
this finding is unclear at present, as BRCA1 mutations have not been associated with epidermal disorders, E2F1 and 
BRCA1 may modulate DNA repair processes in UV-irradiated keratinocytes. 
Signaling through TGF-β receptors in epidermal keratinocytes has multiple effects, including inhibition of 
proliferation and increased migration, but not induction of differentiation [45].  One mechanism for the antiproliferative 
effect of TGF-β involves nuclear translocation of pre-existing cytoplasmic complexes that contain Smad3 and E2F4 or 
E2F5, which bind to the c-myc promoter, thus repressing its transcription. TGF-β also induces down-regulation of E2F1, 
-2 and -3 [35, 46] and signaling through Smad7, which results in E2F1 mRNA down-regulation in keratinocytes [47].  
7.  Role of the Rb family proteins in the epidermis 
Accumulating evidence from cultured cells and transgenic models shows the importance of the pRb family of 
proteins in epidermal morphogenesis. During late mouse embryogenesis, pRb, p107 and p130 transcripts are present the 
epidermis [48]. pRb is present in all mouse post-natal epidermal layers [49], and p130 is expressed in undifferentiated 
and differentiated murine cultured keratinocytes at similar levels [35]. In human epidermis, pRb and p107 proteins are 
expressed in all layers, whereas p130 is restricted to suprabasal keratinocytes [50]. Conflicting data exist for human 
keratinocytes induced to differentiate by culture in suspension. In one report, suspension reduced pRb levels and 
increased p130 abundance relative to undifferentiated cells [51], whereas another study reported little change in the 
abundance of these proteins [52]. 
The roles of the pRb family of proteins have been explored using exogenous expression in cultured cells and 
transgenic mouse models. In HaCaT cells, simultaneous exogenous expression of pRb and p107, or pRb, p107 and p130 
induced growth arrest and expression of the differentiation markers keratin 10 and involucrin [50]. pRb is essential for 
epidermal differentiation and exit from the cell cycle, as mice with inactivation of Rb in the epidermis exhibited 
hyperplasia, DNA synthesis and keratin 14 expression in suprabasal layers normally negative for both, abnormal 
responses to radiation and centrosome synthesis, as well as reduced keratin 10 abundance in suprabasal keratinocytes 
[49].  One of the targets of the E2F/pRb pathway during differentiation is the cdk inhibitor p21, the transcription of 
which is activated directly by pRb [53]. 
Although mice with targeted inactivation of P107 or P130 do not show epidermal alterations, p107-/-/p130-/- double 
mutant animals exhibit impaired differentiation of the interfollicular epidermis and abnormalities in hair follicles [54]. 
This is indicative of a fundamental role for these two proteins in epidermal development, and suggests a degree 
functional redundancy between them. Taken together, the data indicate that pRb family proteins play central and not 
totally overlapping roles in the epidermis, as evidenced by the increased severity in epidermal abnormalities in p107-/-
/p130-/- and pRb-/-/p107-/- double mutant mice, relative to the single null animals [54, 55]. 
A functional link between the E2F/pRb and the BMP signaling pathways has recently been described. The decrease 
in hair follicles and delayed follicle formation observed in p107-/-/p130-/- mice is accompanied by impaired expression 
of BMP-4, an essential follicle morphogen, and of other modulators of BMP signaling, including noggin [54]. Although 
the direct involvement of the E2F/pRb network in BMP4 expression has yet to be explored, clearly there is a genetic 
interaction between these two pathways. Curiously, although these double mutant mice also exhibit increased levels of 
nuclear β-catenin [56], their follicular phenotype contrasts with that of transgenic mice with increased levels of a stable, 
nuclear β-catenin mutant, which show greater hair follicle formation [57]. Folliculogenesis requires multiple interactions 
among signaling pathways and it is possible that in p107-/-/p130-/- mice additional signaling components are abnormal, 
resulting in reduced follicle formation in spite of the apparent increase in nuclear β-catenin. 
Treatment of keratinocytes with TGF-β results in the formation of multiple pRb family complexes, including 
formation of E2F/p130 species associated with repression of cdc2 and cdc25 expression, the latter two proteins being 
indispensable for cell division [58, 59]. 
8.  Role of cyclin-dependent kinases (cdk) in epidermal keratinocytes 
The balance of active (hypophosphorylated) and inactive (hyperphosphorylated) pRb family proteins is partially 
regulated by cdk and their associated cyclins and inhibitors and, consequently, cdk activity is one of the upstream 
regulators of the E2F/pRb pathway. Many of these upstream regulators of E2F and pRb proteins are ubiquitously 
expressed in the epidermis, including cyclins D1, D3, E and A, cdk2, cdk4 and cdk6, as well as the cdk inhibitors p21, 
p27, p57, p15, p16 and p18 [60]. In cultured keratinocytes induced to differentiate by Ca2+ treatment, there is a 
pronounced downregulation of cyclins D1, D2, D3, and E, as well as cdk2, together with an increased abundance of 
cdk4, cdk6 and p21. These changes also reflect reduction in cdk2-associated kinase activity, normally present in 
proliferating cells [61], which generates hypophosphorylated pRb.  
Keratinocytes isolated from p21-/- or p27-/- mice display increased proliferative capacity relative to wild type cells. 
Although the capacity of these mutant cells to exit the cell cycle upon differentiation is unaffected, expression of late 
differentiation markers is also impaired in p21-/- keratinocytes [62]. The epidermis of double mutant mice carrying an 
inactivating mutation in the INK/Arf (which encodes p16 and p19) and p21 loci is morphologically normal. However, 
expression of the differentiation markers keratin 10, filaggrin and loricrin is decreased, and keratin 6 is abnormally 
expressed in the suprabasal layers. Although basal keratinocyte proliferation was enhanced in these mutant cells, their 
ability to exit the cell cycle upon treatment with TGF-β or Ca2+ was unaffected [63]. 
Several mediators crucial for epidermal development act directly upstream from the E2F/pRb pathway. For 
example, sonic hedgehog (Shh) activation of the transcription factors Gli2 and Gli3 is indispensable for folliculogenesis 
[64]. Although, individually, cyclin D1 and cdk4 are dispensable for epidermal formation [65, 66], Shh- or Gli2-null mice 
show decreased cell proliferation in hair follicles due, in part, to impaired cyclin D1 and D2 expression [67]. Conversely, 
exogenous Shh expression in human keratinocytes induces epidermal hyperplasia, proliferation in suprabasal 
keratinocytes, and impaired cell cycle exit upon Ca2+-induced differentiation [68]. Int. J. Biol. Sci. 2005 1  91
The epidermal phenotype of transgenic mouse models has confirmed a positive regulatory effect of D-type cyclins 
and cdk in the epidermis. Mice with targeted cyclin D1, D2 or D3 expression to the basal layer exhibit expansion of 
proliferating layers, and moderate acanthosis and hyperkeratosis, but retain normal differentiation responses [69, 70]. 
Similarly targeted cdk4 expression resulted in increased keratinocyte proliferation and epidermal thickness 
characterized by expansion of the differentiated spinous and granular layers, indicating that differentiation responses 
are operative in these animals.  Sequestration of p27 by cdk4 with concomitant activation of cdk2/cyclin E complexes 
appears to mediate these effects [71]. 
Other pathways regulate keratinocyte proliferation and differentiation through modulation of cdk. For example, 
Ca2+-induced differentiation activates PKCη, which associates with complexes containing p21/cyclin E/cdk2, resulting 
in cdk2 inactivation and generation of hypophosphorylated pRb [72]. In addition, inhibition of keratinocyte 
proliferation by interferon-γ, tumor necrosis factor-α, TGF-β and phorbol esters involves activation of p16 [73]. 
9.  The E2F/pRb pathway in epidermal regeneration and pathogenesis 
Epidermal regeneration after wounding requires a proliferative burst and acquisition of migratory properties in 
keratinocytes [12]. Skin injury in humans triggers a marked up-regulation of E2F1 and E2F2, but not of E2F3 or E2F4 
transcripts. E2F1 and E2F2 are expressed in migrating keratinocytes at the wound margin, as well as in all the layers of 
proliferative keratinocytes in the regenerating epidermis, just behind the migrating cell front [21]. 
Although the hyperproliferative phenotype of keratinocytes in inflammatory disorders such as psoriasis has been 
well documented, the role and regulation of the E2F/pRb pathway has received little attention. Chaturvedi et al. [73] 
have reported heterogenous regulation of the cdk inhibitors p12, p14ARF and p16, with elevated levels of these proteins 
in 33% to 88% of psoriatic samples, suggesting that none of these proteins may play a universal causative role in the 
keratinocyte phenotype observed in this disorder. Cyclosporin treatment of psoriatic plaques induces reduction in 
epidermal proliferation characterized by a reduction in overexpressed cyclins D1, A and B [74], although, paradoxically, 
cyclosporine also interferes with p21 expression in keratinocytes [75]. The role of the E2F/pRb pathway in psoriasis is 
unclear, but pharmacological intervention with agents that regulate cell cycle proteins could aid in the therapy of this 
disorder. 
Several lines of evidence implicate the E2F/pRb pathway in carcinogenesis. In pre-cancerous actinic keratoses and 
in seborrhoeic keratoses, a condition caused by excessive sunlight exposure, but not in normal epidermis, weak to 
moderate p16 expression has been detected. In contrast, progression to squamous cell carcinoma is associated with high 
p16 expression  [76, 77].  Correlative studies between E2F expression and clinical outcomes in human tumors indicate 
that the consequences of changes in E2F expression depend on multiple factors, including tissue type and status of other 
cell growth regulators, such as pRb, p53 and p16 [78]. E2F1 amplification associated with poor prognosis occurs in 
esophageal squamous cell carcinomas, suggesting association between abnormal E2F regulation and tumorigenesis in 
squamous epithelia [79, 80]. However, the status of E2F1 in epidermal squamous cell carcinomas has yet to be 
investigated.  
Experimental tumorigenic treatments in mouse epidermis result in up-regulation of E2F1, -2, -4 and –5, p16 and 
p57, as well as increased abundance of cdk4-containing complexes during pre-malignant progression [81, 82]. 
Overexpression of E2F1 targeted to basal keratinocytes in transgenic mice induces epidermal hyperplasia and tumor 
formation with long latency, and cooperates with Ha-ras or p53 inactivation in tumor induction [83, 84, 85]. These E2F1 
transgenic animals were resistant to experimental carcinogenesis, likely due to increased levels of apoptosis, unlike 
transgenic mice overexpressing E2F4 in basal keratinocytes, which developed larger tumors [86].  Finally, transgenic 
mice expressing DP1 targeted to the basal layer exhibited increased tumor size and numbers when subjected to 
experimental carcinogenesis protocols, but not spontaneously, indicating that DP1 deregulation may facilitate tumor 
formation subsequent to other insults [87]. Cyclin D1 is necessary for epidermal tumor formation, as in similar 
carcinogenesis models, cyclin D1-null mice develop lesions with reduced frequency compared with wild type animals 
[88], whereas transgenic mice expressing cdk4 in basal keratinocytes present high rates of squamous cell carcinoma 
formation [89]. 
Exposure to ultraviolet (UV) radiation is a major risk factor for the development of epidermal tumors. Following 
epidermal exposure to UV-B, p16 and p21 protein levels increase [90], possibly to mediate growth arrest associated with 
UV-induced DNA damage. Notably, absence of E2F1 increases UV-induced keratinocyte apoptosis, in stark contrast 
with the well established role of this protein in induction of apoptosis in other systems [91]. 
10. Conclusions 
Impressive progress has been made in elucidating the functions and mechanisms of action of the various 
components of the E2F/pRb pathway. This pathway is now recognized as a crucial network in the regulation of tissue 
development, remodeling and homeostasis. The involvement of alterations in the E2F/pRb network in the formation of 
epidermal tumors has been suggested by recent experimental evidence, and modulation of this pathway may represent 
an effective therapeutic tool for a variety of epidermal disorders.  
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Figures 
Fig. 1. Architecture of the Skin. In the skin, the dermis and the  epidermis are separated by a basement membrane. The epidermis 
is formed by a lower basal layer, and several suprabasal layers. the uppermost suprabasal layer is the cornified envelope (ce). 
 
Fig. 2. Schematic structure of the E2F family of transcription factors.  All member of the E2F subgroup contain a DNA-binding 
domain (DNA). E2F1 through –6 contain a leucine-zipper dimerization domain that mediates interactions with DP proteins (DP), 
and E2F1 through 3 also have a cyclin A-binding region (CycA). C-terminal transactivation domains that mediate binding of E2F1 
through –5 to pRb family proteins are also indicated. E2F7 has two DNA-binding domains and lacks DP- and pRb-binding regions. 
DP proteins only have DNA and E2F-binding domains. 
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Fig. 3. Regulation of G1/S transition by the E2F/pRb pathway.  A. During G0 and early G1 phases, hypophosphorylated  pRb 
family proteins form transcriptional repressor complexes that also contain histone deacetylace (HDAC) activity. B. Mitogenic 
stimulation activates cyclin D/cdk4 and/or cyclin D/cdk6 activity, resulting in pRb protein phosphorylation.  Cyclin D/cdk 
complexes can be negatively regulated by cdk inhibitors (p15,  p16, p18 and p19). C. Phosphorylation of pRb family proteins results 
in their dissociation from E2F factors, which, in turn allows activation of transcription by E2F. Some activator E2F complexes also 
contain hitone acetylase activitiy. E2F activation results in transcription of a variety of genes, including those encoding enzymes 
necessary for DNA replication and repair. 
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